2018 Saw Record Launches, But No Big Splash
Executive Summary
The number of US drug approvals in 2018 was striking, but most of the novel products launched last year are for rare diseases or niche cancers, meaning commercial success may be in the eye of the beholder.
You may also be interested in...
2020 Drug Launches, Like Everything, Will Be Remembered For COVID-19
Gilead's Veklury for the treatment of COVID-19 was a clear commercial standout among new drugs in 2020, but cancer drugs like Seagen's Padcev and Tukysa are poised for long-term potential.
2019 Drug Launches: New Specialty And Rare Disease Blockbusters Take Shape
Novartis' Zolgensma and Pfizer's Vyndaqel were two of the early commercial standouts in 2019, on a likely blockbuster trajectory, while AbbVie's Skyrizi is poised to be fierce competitor in psoriasis.
AbbVie Revs Up The Race To Market In Uterine Fibroids
AbbVie and Neurocrine submitted an NDA to FDA for elagolix for bleeding associated with uterine fibroids, leading in what is expected to be a competitive market.